cIAP Pan-specific Antibody (Mouse mAb) [B1J9]

Catalog No.: F6710

    Application: Reactivity:
    • Lane 1: Raji, Lane 2: Jurkat
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:2000
    Application
    WB
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    68 kDa 80 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Raji cells; Jurkat cells; SW3T3 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

    Datasheet & SDS

    生物学的記述

    Specificity
    cIAP Pan-specific Antibody (Mouse mAb) [B1J9] detects endogenous levels of total cIAP Pan-specific protein.
    タンパク質の局在
    細胞質、細胞核
    Uniprot ID
    Q13489
    Clone
    B1J9
    Synonym(s)
    Cellular inhibitor of apoptosis 2 (C-IAP2), IAP homolog C, hIAP-1; hIAP1, RING finger protein 49, BIRC3, API2, MIHC, RNF49
    Background
    cIAP1 and cIAP2 are closely related inhibitor of apoptosis family members with N‑terminal tandem baculoviral IAP repeat domains, a central caspase‑recruitment domain, and a C‑terminal RING finger that confers ubiquitin E3 ligase activity, positioning them as scaffold enzymes at TNF receptor–associated signaling complexes and other receptor platforms. The BIR domains bind caspases and other signaling proteins, but sequence analyses and mutagenesis show that cIAP BIRs have substitutions in key residues required for tight caspase inhibition, so their primary biochemical activity arises from RING‑dependent ubiquitination rather than potent direct caspase blockade. The RING domain dimerizes and interacts with ubiquitin‑charged E2 enzymes, catalyzing K63 and other polyubiquitin chains on substrates such as RIP1 at the TNF receptor 1 complex, which creates docking sites for TAK1, IKK, and other NF‑κB pathway components and supports prosurvival and proinflammatory transcriptional responses after TNFα stimulation. Either cIAP1 or cIAP2 is sufficient to maintain RIP1 polyubiquitination and NF‑κB activation upon TNFα treatment, and genetic loss of both proteins leads to reduced RIP1 ubiquitination, diminished NF‑κB signaling, and increased formation of RIP1–FADD–caspase‑8 complexes that execute apoptosis. cIAPs also autoubiquitinate and ubiquitinate other adaptors in TNF and related pathways, contributing to turnover of components and to the balance between survival signaling and cell death complexes in response to cytokine and pattern‑recognition receptor inputs. Mitochondria‑derived Smac/DIABLO and HtrA2/Omi bind the BIR domains through IAP‑binding motifs and promote RING‑dependent autoubiquitination and proteasomal degradation of cIAP1 and cIAP2, which lowers cellular cIAP levels and shifts signaling from NF‑κB activation toward caspase‑8 activation and apoptosis in death receptor pathways. Small‑molecule Smac mimetics bind cIAP BIRs, relieve intramolecular inhibition of the RING domain, induce rapid RING‑mediated autoubiquitination, and trigger proteasomal clearance of cIAP1 and, to a lesser extent, cIAP2, providing a tool to experimentally deplete cIAPs and study the resulting switch from prosurvival to proapoptotic signaling. Elevated cIAP1 and cIAP2 expression is reported in multiple cancers, and their E3 ligase activity toward RIP1 and other targets has been linked to maintenance of constitutive NF‑κB activity and survival of malignant cells under stress, while pharmacologic or genetic disruption of cIAP function sensitizes tumor cells to TNF family ligands and chemotherapeutic agents.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください